Month: September 2022

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022. The Company’s webcast presentation will be available for viewing at 9:00am ET on Wednesday, September 28, 2022, on the Company’s website at Events & Presentations or https://investors.mannkindcorp.com/events-and-presentations. The webcast will also be archived and available for replay. Management will be participating in virtual one-on-one meetings throughout the event....

VANCOUVER, British Columbia, Sept. 21, 2022 (GLOBE NEWSWIRE) — Methanex Corporation (the “Company” or “Methanex”) (TSX:MX) (NASDAQ:MEOH) announced today that the Toronto Stock Exchange (the “TSX”) has approved the Company’s previously announced Normal Course Issuer Bid (“NCIB”). Pursuant to the NCIB, the Company will purchase for cancellation up to 3,506,405 common shares (“Shares”), representing 5% of the 70,128,109 Shares issued and outstanding as of September 15, 2022. Purchases will be made on the open market through the facilities of the TSX and will commence on September 26, 2022 and end no later than September 25, 2023. Any purchases will be made from time to time at the then current market price of the Shares and all Shares purchased under the NCIB will be cancelled. Subject to certain exceptions for block purchases,...

Publication includes the Phase 3 VALOR SOD1-ALS trial and its open-label-extension study, underscoring the importance of these longer-term data 12-month data show earlier initiation of tofersen slowed decline across critical measures of function and strength in people diagnosed with SOD1-ALS Results offer important learnings regarding the biology of SOD1-ALS and design of ALS clinical trialsCAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that The New England Journal of Medicine (NEJM) has published detailed results from the Phase 3 VALOR study and the combined analysis of VALOR and its open label extension (OLE) study evaluating tofersen for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). There is currently no treatment targeted for SOD1-ALS. “I...

AI-driven MCI Dermatology Connect speeds access to specialists TORONTO, Sept. 21, 2022 (GLOBE NEWSWIRE) — MCI Onehealth Technologies Inc. (“MCI”) (TSX: DRDR), a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, and Oro Health, a provider of Asynchronous Telemedicine combined with artificial intelligence-based solutions for medical specialists, today announced the launch of collaboratively developed MCI Dermatology Connect. The launch of MCI Dermatology Connect will help meet the need of Ontarians currently waiting for a consultation on minor dermatological conditions, lessen wait times and increase Ontarians’ access to Dermatologists regardless of geographic constraints. “Quick, convenient access to specialists with top-quality continuity of care is a cornerstone of the patient...

TORONTO, Canada, Sept. 21, 2022 (GLOBE NEWSWIRE) — Shawcor Ltd. (“Shawcor” or the “Company“), (TSX: SCL) today announced that the Toronto Stock Exchange (the “TSX”) has approved the Company’s notice of intention to commence a normal course issuer bid (the “Bid”) for common shares of the Company (the “Common Shares”). Pursuant to the Bid, Shawcor may purchase for cancellation up to 5,685,630 Common Shares, representing approximately 10% of Shawcor’s public float (the “Maximum”). Pursuant to the terms of the notes indenture dated December 10, 2021 governing Shawcor’s senior unsecured notes, Shawcor is limited to purchasing a maximum of C$25 million in aggregate repurchases of Common Shares under the Bid based on the actual price paid for such repurchased Common Shares pursuant to the Bid. The Bid will commence...

COLLINGWOOD, Ontario, Sept. 21, 2022 (GLOBE NEWSWIRE) — The Limestone Boat Company (the “Company”) (TSXV: BOAT | OTCQB: LMSBF) – owner and builder of Aquasport Boats, Limestone® Boats and Boca Bay Boats – is pleased to announce that it has placed an initial order for the first fully electric propulsion systems to be installed on its 2024 Model Year EV boats following the successful sea trial results of its Vision Marine (NASDAQ: VMAR) E-Motion™ electric outboard-powered Aquasport 2100CC this summer. The in-water testing fully validated the Company’s EV engine partner Vision Marine as the preeminent provider of high-performance electric power in the recreational boating market, yielding impressive speed, operating and recharging times, and handling results. The new EV model will debut later this month in the Vision Marine Technologies...

MIAMI, Sept. 21, 2022 (GLOBE NEWSWIRE) — PennantPark Floating Rate Capital Ltd. (the “Company”) (NYSE: PFLT) (TASE: PFLT) announced that it increased the size of its multi-currency, senior secured credit facility (as amended, the “Credit Facility”) from $300 million to $366 million and replaced the London interbank offer rate, or LIBOR, benchmark provisions with secured overnight financing rate, or SOFR, benchmark provisions. All other terms remain unchanged. “We are pleased to have upsized our Credit Facility and it nicely complements our unsecured bonds and permanent equity base. We are delighted with the continued confidence and support from our lending partners,” said Chairman and Chief Executive Officer Arthur H. Penn, adding “This increased facility will expand our ability to serve middle-market sponsor and borrower clients...